Question special

Last year in our discussion of the LEAP trial, we had an interesting conversation ( about the clinical role of monitoring peanut-specific IgG4 levels (and IgG4:IgE ratios) but ultimately concluded that evidence was insufficient to start doing this for routine clinical care. I am wondering if, in the year since LEAP was published, our experts have been incorporating this into their clinical practice? Any other comments on this issue?